Skip to main content Back to Top
Advertisement

1/10/2022

Levetiracetam Extended-Release Tablets

Reason for the Shortage

    • Apotex has levetiracetam extended-release tablets available.
    • Lupin has levetiracetam extended-release tablets available.
    • OWP discontinued their Roweepra XR formulations.
    • Sun Pharma has levetiracetam extended-release tablets available.
    • Torrent has discontinued their levetiracetam extended-release tablets.

Available Products

    • Keppra XR oral extended release tablet, UCB, 500 mg, bottle, 60 count, NDC 50474-0598-66
    • Keppra XR oral extended release tablet, UCB, 750 mg, bottle, 60 count, NDC 50474-0599-66
    • Levetiracetam oral extended release tablet, Apotex, 500 mg, bottle, 60 count, NDC 60505-3280-06
    • Levetiracetam oral extended release tablet, Apotex, 750 mg, bottle, 60 count, NDC 60505-3517-06
    • Levetiracetam oral extended release tablet, Lupin, 500 mg, bottle, 60 count, NDC 68180-0117-07
    • Levetiracetam oral extended release tablet, Lupin, 750 mg, bottle, 60 count, NDC 68180-0118-07
    • Levetiracetam oral extended release tablet, Sun Pharma, 500 mg, bottle, 60 count, NDC 47335-0573-86
    • Levetiracetam oral extended release tablet, Sun Pharma, 750 mg, bottle, 60 count, NDC 47335-0576-86

Updated

Updated January 10, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 6, 2019 by Anthony Trovato, PharmD, BCPS. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT